688166 博瑞医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入874,250-10.50%1,282,5521,179,5181,017,3311,052,409
减:营业总成本859,6717.68%1,102,599980,323783,331789,486
    其中:营业成本424,9273.58%544,951521,414376,299460,671
               财务费用34,09714.86%40,90924,1409,8005,740
               资产减值损失(2,757)-47.32%(19,943)(21,490)(14,649)(9,396)
公允价值变动收益1,51449.93%(5,700)(520)(3,395)790
投资收益(11,754)21.99%(11,634)(14,741)3,9579,231
    其中:对联营企业和合营企业的投资收益(7,884)10.10%(9,162)(13,605)(8,917)(9,236)
营业利润22,773-86.47%160,289190,244242,155258,991
利润总额22,415-86.66%157,201188,770242,207257,455
减:所得税费用(8,972)-142.08%15,93715,34630,78019,897
净利润31,387-78.61%141,263173,424211,427237,558
减:非控股权益(18,933)-38.23%(47,904)(29,042)(28,196)(6,393)
股东净利润50,320-71.64%189,167202,466239,623243,951

市场价值指针
每股收益 (元) *0.120-71.43%0.4500.4800.5800.600
每股派息 (元) *----0.0960.0960.1140.120
每股净资产 (元) *5.6414.68%5.4895.4285.0094.093
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容